• Prophylaxis and Therapy (delayed treatment)
  • (Deep) sequencing, mutation-specific PCR
  • Any route of drug administration possible (IV, oral, nebulizer, etc.)
  • Read outs include: clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc.
  • Virus transmission

PLoS Pathog. 2011 Sep;7(9):e1002276.

Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.

van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van Amerongen G, Schutten M, Kuiken T, Osterhaus AD, Fouchier RA, Boucher CA, Herfst S.

  PLoS One. 2010 Feb 8;5(2):e9106.

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J.

  ESWI conference, Portugal, 2008

Delayed oseltamivir treatment of influenza virus A/turkey/Turkey/1/2005 (H5N1) infection in ferrets.

Stittelaar KJ, van Lavieren RF, van Amerongen G, Smith J, Klumpp K, Fouchier RAM,  Simon J, Osterhaus AD.